Day One Biopharmaceuticals
2000 Sierra Point Parkway
Suite 501
Brisbane
CA
94005
United States
Tel: 1-650-484-0899
Website: https://dayonebio.com/
Email: info@dayonebio.com
About Day One Biopharmaceuticals
Day One Biopharmaceuticals understands that advances in cancer research now enable drug developers to identify children and adults who may benefit from the same medicine. We are a unique company created to find and develop new therapies that meet the critical needs of people of all ages living with cancer – starting from the biology of childhood cancer. Our distinctive approach, together with our trusted network of pediatric oncology investigators, gives us an unparalleled ability to advance promising discoveries for patients of any age. We are ready to pursue the full potential of our therapies to improve the greatest number of lives as quickly as possible.
56 articles about Day One Biopharmaceuticals
-
Day One Biopharmaceuticals aims to provide a business solution to a moral problem: the inequity in pediatric oncology drug development.
-
Day One Reports Second Quarter 2022 Financial Results and Corporate Progress
8/4/2022
Day One Biopharmaceuticals, a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, announced financial results for the second quarter of 2022 and highlighted recent corporate achievements.
-
Day One to Participate in the 2022 Wedbush PacGrow Healthcare Virtual Conference
8/2/2022
Day One Biopharmaceuticals announced that management will participate in a panel discussion at the 2022 Wedbush PacGrow Healthcare Virtual Conference.
-
Day One Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
6/21/2022
Day One Biopharmaceuticals, Inc. announced the closing on June 17, 2022 of its previously announced upsized underwritten public offering of 11,500,000 shares of its common stock, including the full exercise of the underwriters’ option to purchase 1,500,000 additional shares, at a public offering price of $15.00 per share.
-
Day One Announces Pricing of Upsized Public Offering of Common Stock - June 15, 2022
6/15/2022
Day One Biopharmaceuticals, Inc. announced the pricing of its upsized underwritten public offering of 10,000,000 shares of its common stock at a public offering price of $15.00 per share.
-
Day One Biopharmaceuticals announced positive early data assessing tovorafenib as a once-a-week treatment in people aged six months to 25 years with relapsed or progressive pediatric low-grade glioma.
-
Day One Announces Proposed Public Offering of Common Stock
6/14/2022
Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that it has commenced an underwritten public offering of $125.0 million of shares of its common stock.
-
Day One Announces Positive Initial Data from Pivotal FIREFLY-1 Trial of Tovorafenib (DAY101) in Relapsed Pediatric Low-Grade Glioma
6/12/2022
Day One Biopharmaceuticals announced positive initial data from the first 22 Response Assessment for Neuro-Oncology -evaluable patients enrolled in the ongoing, open-label, single-arm, pivotal Phase 2 FIREFLY-1 clinical trial.
-
A roundup of last week's top clinical trial announcements and news, including updates from Pfizer, BioNTech, Ocugen and more.
-
Day One Announces First Patients Dosed in Phase 1b/2 Combination Study with Tovorafenib (DAY101) and Pimasertib in RAF-altered Solid Tumors
5/23/2022
Day One Biopharmaceuticals today announced the first patients have been dosed in sub-study 2 of FIRELIGHT-1, a Phase 1b/2 clinical trial evaluating tovorafenib (DAY101) in combination with pimasertib.
-
Day One Reports First Quarter 2022 Financial Results and Provides Business Update
5/12/2022
Day One Biopharmaceuticals announced financial results for the first quarter of 2022 and highlighted recent corporate achievements.
-
Day One to Present at the 21st Annual Needham Virtual Healthcare Conference
4/6/2022
Day One Biopharmaceuticals announced that management will present at the 21st Annual Needham Virtual Healthcare Conference on Wednesday, April 13 at 3:45 p.m. ET.
-
Day One Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Progress
3/7/2022
Day One Biopharmaceuticals, a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, announced its fourth quarter and full year 2021 financial results and highlighted recent corporate achievements.
-
Day One to Participate in the Cowen 42nd Annual Health Care Conference
2/28/2022
Day One Biopharmaceuticals announced management will participate in a fireside chat at the Cowen 42nd Annual Health Care Conference on Monday, March 7 at 2:50 p.m. ET.
-
Day One to Present at the 40th Annual J.P. Morgan Healthcare Conference
1/5/2022
Day One Biopharmaceuticals announced that Dr. Jeremy Bender, chief executive officer, will present virtually during the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11 at 10:30 a.m. ET.
-
Day One Announces First Patient Dosed in Phase 2 Monotherapy Study in RAF-altered Solid Tumors
11/22/2021
Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for patients of all ages with genomically-defined cancers, today announced that the first patient has been dosed in a Phase 2 clinical trial evaluating DAY101 as a monotherapy in patients with RAF-altered solid tumors.
-
Day One to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference
11/18/2021
Day One Biopharmaceuticals today announced that management will participate in a fireside chat discussion at the Piper Sandler 33rd Annual Virtual Healthcare Conference.
-
Day One Reports Third Quarter 2021 Financial Results and Corporate Progress
11/8/2021
Day One Biopharmaceuticals, a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for patients of all ages with genomically defined cancers, announced financial results for the third quarter of 2021 and highlighted recent corporate achievements.
-
Day One Announces Presentation at 2021 Connective Tissue Oncology Society (CTOS) Virtual Annual Meeting
11/3/2021
Day One Biopharmaceuticals today announced an upcoming poster presentation at the 2021 Connective Tissue Oncology Society (CTOS) Virtual Annual Meeting, being held from November 10-13, 2021.
-
Day One Appoints Scott Garland to Board of Directors
8/17/2021
Day One Biopharmaceuticals, a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for patients of all ages with genomically defined cancers, announced the appointment of Scott Garland to the Company’s board of directors.